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Abstract
Rationale: Positive margin status due to incomplete removal of tumor tissue during breast conserving surgery
(BCS) is a prevalent diagnosis usually requiring a second surgical procedure. These follow-up procedures
increase the risk of morbidity and delay the use of adjuvant therapy; thus, significant efforts are underway to
develop new intraoperative strategies for margin assessment to eliminate re-excision procedures. One
strategy under development uses topical application of dual probe staining and a fluorescence imaging strategy
termed dual probe difference specimen imaging (DDSI). DDSI uses a receptor-targeted fluorescent probe and
an untargeted, spectrally-distinct fluorescent companion imaging agent topically applied to fresh resected
specimens, where the fluorescence from each probe is imaged and a normalized difference image is computed
to identify tumor-target distribution in the specimen margins. While previous reports suggested this
approach is a promising new tool for surgical guidance, advancing the approach into the clinic requires
methodical protocol optimization and further validation.
Methods: In the present study, we used breast cancer xenografts and receiver operator characteristic (ROC)
curve analysis to evaluate a wide range of staining and imaging parameters, and completed a prospective
validation study on multiple tumor phenotypes with different target expression. Imaging fluorophore-probe
pair, concentration, and incubation times were systematically optimized using n=6 tissue specimen replicates
per staining condition. Resulting tumor vs. normal adipose tissue diagnostic performance were reported and
staining patterns were validated via receptor specific immunohistochemistry colocalization. Optimal staining
conditions were tested in receptor positive and receptor negative cohorts to confirm specificity.
Results: The optimal staining conditions were found to be a one minute stain in a 200 nM probe solution (area
under the curve (AUC) = 0.97), where the choice of fluorescent label combination did not significantly affect
the diagnostic performance. Using an optimal threshold value determined from ROC curve analysis on a
training data set, a prospective study on xenografts resulted in an AUC=0.95 for receptor positive tumors and
an AUC = 0.50 for receptor negative (control) tumors, confirming the diagnostic performance of this novel
imaging technique.
Conclusions: DDSI provides a robust, molecularly specific imaging methodology for identifying tumor tissue
over benign mammary adipose tissue. Using a dual probe imaging strategy, nonspecific accumulation of
targeted probe was corrected for and tumor vs. normal tissue diagnostic potential was improved,
circumventing difficulties with ex vivo tissue specimen staining and allowing for rapid clinical translation of this
promising technology for tumor margin detection during BCS procedures.
Key words: breast conserving surgery, fluorescence, image-guided surgery, tumor margin assessment, breast cancer, dual
probe imaging, dual probe difference specimen imaging

Introduction
Breast conserving surgery (BCS), including
partial mastectomy and lumpectomy, remains the

most common treatment option for patients with early
stage breast cancer and is carried out for 61% of the
http://www.thno.org
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~200,000 breast cancer patients diagnosed annually in
the United States [1]. However, despite recent
technological advances and efforts to improve
surgical methods, 20-60% of these patients are left
with involved or close surgical margins, determined
by pathological assessment following completion of
the surgery [1, 2]. Pathological findings of involved or
close margins require follow up re-excision surgery
within days to weeks of the original excision,
resulting in increased risk of morbidity, undue patient
stress, increased cost to both the patient and
healthcare system, as well as delay of adjuvant
therapy, all negatively affecting patient outcomes
[2-6]. Technologies currently deployed in the clinic to
improve margin detection include frozen section
analysis (FSA) [7], touch prep cytology [8], specimen
radiography [9], specimen ultrasound [10], and
radiofrequency spectroscopy [11]. Each technique has
shown improvement in tumor re-excision rates, but
sensitivity and specificity performance has been
mixed and lengthy tissue processing procedures in
some cases limit translation to the clinic [7, 8, 12-20].
It has thus been recognized that rapid, accurate
approaches that do not compromise tissue integrity
are needed and widespread efforts are underway to
develop novel approaches for intra-surgical margin
assessment. A multitude of optical techniques are
under development for this application [8, 21-35].
These strategies are in various stages of clinical
translation where the ability to produce high contrast
and high-resolution images have been demonstrated,
but requirements of long scan times and in vivo
application of exogenous contrast agents diminish
clinical viability. While in vivo administration of
fluorescent contrast agents is attractive, since it
enables imaging guidance within the surgical cavity,
the availability of clinically approved contrast agents
is limited and securing approval for new agents with
appropriate safety profiles is a long and challenging
process [36, 37]. Topical application of tumor-specific
fluorescent probes is a conceptually simple approach
to identify tumor in specimen margins and an
appealing alternative to the difficulties of in vivo
contrast agent administration. In one iteration of this
approach, activatable fluorescent probes were used to
detect the presence of tumor-specific enzyme,
marking positive tumor margins [38-40]. An
orthogonal approach uses fluorescently-labeled
tumor targeting moieties (such as antibodies,
antibody fragments, peptides, etc.) to rapidly stain,
wash and image the excised specimen. In principle,
this technique enables rapid tumor-receptor-specific
staining of the specimen without compromising
follow-up pathology and doesn’t require the safety
profile of agents administered in vivo.
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However, early efforts to deploy this simple
strategy produced non-specific uptake of targeted
fluorescent probes in normal tissue despite efforts to
apply blocking solution prior to staining, particularly
in surrounding adipose tissue, a main component of
resected breast specimens. Thus, simple, single-agent
staining of excised tissue specimens, including tissues
from BCS resulted in poor diagnostic performance. To
address this, we and others have shown that
non-specific uptake can be quantified and removed by
including a second non-specific companion imaging
probe in the staining solution and that the targeted
and untargeted images together improve cancer
detection [31-35, 41, 42]. In this paradigm, each probe
is labeled with a spectrally-distinct fluorophore,
enabling the specific and non-specific probe
distribution to be assessed with multi-color imaging.
The targeted and untargeted probe pairs are chosen to
have similar molecular weights in an attempt to
ensure similar tissue transport kinetics of both agents.
Therefore, the normalized difference between the
targeted and untargeted probes’ fluorescence
emphasizes the difference between each probe’s
uptake, enhancing the signal from the tumor
biomarker-targeted probe. The resulting image is thus
a direct representation of the targeted probe’s specific
binding to the tumor biomarker. We have termed this
approach Dual-Probe Difference Specimen Imaging
(DDSI). We previously reported a proof-of-concept
study for the DDSI technique using a HER2-targeted
probe and a spectrally distinct untargeted probe [41].
While the DDSI technique showed a significant
increase in tumor to surrounding adipose tissue
contrast and improved diagnostic performance when
compared to targeted stain alone, the staining
protocol was not optimized for speed and diagnostic
accuracy, and many questions remained unanswered.
To date, a full investigation of the relevant parameter
space, including stain concentration, incubation times,
and fluorescent labels has not been reported.
In this study, we explored this parameter space
in an effort to optimize the DDSI staining protocol for
future clinical translation. Throughout this study, we
used receiver operator characteristic (ROC) curve
analysis as the metric of evaluation, and acquired
confirmatory immunohistochemistry (IHC) and
hematoxylin and eosin (H&E) stained microscopy
images of tissue samples. In the first set of
experiments, we examined the effect of stain
concentration and incubation time on the diagnostic
performance of HER2-targeted DDSI imaging, with
the aim of choosing the condition that provided the
highest diagnostic performance in a short time. Next,
in an effort to confirm that the reported diagnostic
performance was not driven or otherwise affected by
http://www.thno.org
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the binding behavior of the fluorescent label itself, an
underappreciated issue in fluorescence imaging of
tissue [43], we examined the effect of switching the
fluorescent labels between targeted and untargeted
probes. Finally, to evaluate the diagnostic
performance in a semi-blinded, pre-clinical study, we
used ROC curve analysis on a training data set to
define an optimal diagnostic threshold and applied
this result prospectively to a data set that included
normal tissue, HER2(+) tumors and HER2(-) tumors.

Materials & Methods
General Study Design
The three primary objectives of this study were:
1. Identify a tissue staining/washing protocol
that provided high diagnostic performance within a
clinically relevant time frame that stained the
target-of-interest. This was accomplished by repeating
DDSI imaging for different staining concentrations
and incubation times (100 and 200 nM, 1 and 10 min),
where six replicates per condition were completed
(Fig. 1).
2. Confirm that the fluorophore label did not
have a major impact on diagnostic performance. This
was accomplished by repeating all staining conditions
(100 and 200 nM, 1 and 10 min, 6 replicates per
condition), with the fluorescent labels reversed
between the targeted and untargeted probes (Fig. 1).
3. Determine the diagnostic accuracy of the
optimized DDSI method. This was accomplished by
selecting the optimal staining condition once
parameter optimization studies were completed with
6 replicate tumor and adipose tissue pairs per
condition. A diagnostic threshold derived from ROC
curve analysis on a training data set was then
determined and used on a prospective testing data set
that included normal tissue, HER2(+) and HER2(-)
tumors. Six replicates per HER2 expression condition
were used for the testing data set experiments.
For each replicate, tumor and normal adipose
tissues were stained with the DDSI protocol resulting
in a total of 60 tissue pairs. Color and fluorescence
images were acquired using a custom-built widefield
imaging system capable of acquiring co-registered
images of each probe’s fluorescence. Following DDSI
image processing and analysis, each condition’s
performance was evaluated using ROC curve analysis
as assessed through the area under the curve (AUC)
to determine tumor vs. normal tissue diagnostic
performance. Confirmatory Her2-IHC and H&E were
also completed for each sample.

Fluorophores & Antibodies
Alexa Fluor 647 (AF647, Thermo Fisher
Scientific, Waltham, MA) and Cy3B (GE Healthcare
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Life Sciences, Little Chalfont, UK) were used for all
fluorescence imaging studies. These fluorophores
were selected because they are photostable, have
relatively high quantum yields and are readily
available. Each fluorophore was purchased in its
N-hydroxysuccinimide (NHS) ester form and
solubilized in anhydrous DMSO at 10 mM for
antibody
conjugation
reactions.
Trastuzumab
(Herceptin, Genentech, South San Francisco, CA,
molecular weight (MW) = 145.5 kDa) was used as the
targeted probe for all studies. Lyophilized Herceptin
was made into a stock solution at 2 mg/mL using 1x
phosphate buffered saline (1x PBS) at pH 7.4. Donkey
anti-rabbit IgG (Jackson ImmunoResearch, West
Grove, PA, MW = 150 kDa) was used as the
untargeted probe for all studies.

Mice & Cell Lines
The MCF7 parent line and MCF7 cell line
transfected with HER2/neu (MCF7-HER2) [44] were
grown to 90% confluence and harvested for tumor
implantation. 32-38 day old female athymic nude
mice (Homozygous 490, Charles Rivers Labs,
Wilmington, MA) weighing 19-21 g were used for
growth of MCF7-HER2 and MCF7 tumor xenografts.
All animal studies were approved by the Institutional
Animal Care and Use Committee (IACUC) at Oregon
Health and Science University (OHSU).

Tumor Implantation & Growth
Four days prior to MCF7-HER2 implantation,
mice were implanted with 0.72 mg/pellet 90 day
release 17β-estradiol pellets (Innovative Research of
America, Sarasota, FL), explained as follows. One
hour prior to pellet implantation, mice were injected
intraperitoneally (IP) with 0.05 mg/kg buprenorphine
(Reckitt Benckiser Pharmaceuticals Inc., Slough, UK)
to mitigate any pain from the procedure. Mice were
then anaesthetized with 100 mg/kg ketamine
(Hospira Inc., Lake Forest, IL) and 10 mg/kg xylazine
(AnaSed, Shenandoah, IA) injected IP. Depth of
anesthesia was assessed using the toe pinch method to
ensure mice were fully anesthetized prior to any
surgical manipulation. In a sterile surgical field, the
lateral dorsal neck of the mice was sterilized with
povidine-iodine (Purdue Products, Stamford, CT). A
small incision (~5 mm) was made on the right side of
the neck between the right ear and shoulder using
autoclaved instruments and a single 17β-estradiol
pellet was placed beneath the skin using a 10-gauge
trochar (Innovative Research of America, Sarasota,
FL). The incision was sealed with Vetbond (3M, St.
Paul, MN) and monitored over the next week for
healing. Estradiol implantation is necessary for MCF7
cell line tumorigenicity [44].
http://www.thno.org

Theranostics 2017, Vol. 7, Issue 19

4725

Fig. 1: Staining protocol and experimental conditions. (A) Schematic of DDSI staining protocol and imaging approach. The parameters for each step of the
staining protocol are listed in their respective boxes. The dual-stain soak experimental parameters that were optimized are highlighted in red. DDSI image processing
was performed by subtracting the untargeted image from the targeted image and then dividing by the untargeted image as shown. (B) Table of experimental
conditions tested to optimize the staining protocol.

Four days later, MCF7-HER2 tumors were
implanted, detailed as follows. Mice were
anaesthetized with 100 mg/kg ketamine and 10
mg/kg xylazine injected IP. The peritoneal region of
the animal was sterilized with providine-iodine in a
sterile surgical field. A small incision (~3 mm) was
made bilaterally adjacent to the inferior nipple on the
left and right sides of each mouse. Forceps were used
to retract the mammary adipose pad through the
incision followed by a 200 µL injection of MCF7-HER2
cell suspension (1x106 cells) into each mammary
adipose pad. The injected mammary adipose pad was
carefully inserted back through the incision after
which the incision was sealed with Vetbond. All
incisions were monitored daily for a week to ensure
healing. Mice were monitored weekly for tumor
growth and overall health. The tumors were allowed
to grow for 4-6 weeks or until tumor diameter reached
1 cm3 as measured by calipers.
The training data set consisted of a cohort of 15
mice implanted with MCF7-HER2 tumors bilaterally
for optimization of the dual probe staining
concentration and incubation time. Of the 30 total
implantation sites, 24 tumors grew, which were
bisected and used in the optimization studies. A
second cohort of 2 mice were implanted with
MCF7-HER2 tumors for a testing set for staining with
the selected optimal probe pair, protein concentration
and incubation time. Of the 4 total implantation sites,
3 tumors grew, which were bisected and used in the
testing set. An additional cohort of 3 mice were
implanted with the MCF7 parent cell line bilaterally
for a testing set with HER2 negative tumors. Of the 6

total implantation sites, 3 tumors grew, which were
bisected and used in the testing set.

Antibody-Fluorophore Conjugations
Each antibody was conjugated to each
fluorophore, resulting in the following labeled
antibodies:
Herceptin-AF647,
Herceptin-Cy3B,
DkRb-AF647, and DkRb-Cy3B, which were prepared
individually as follows. The antibody was buffer
exchanged into 1x PBS, pH 8.0 at a concentration of
2.0 mg/mL for Herceptin and 1.3 mg/mL for DkRb.
1.5 µL of the 10 mM fluorophore stock solution in
anhydrous DMSO was added to 220 µL of Herceptin
and 1 µL of 10 mM fluorophore stock solution in
anhydrous DMSO was added to 220 µL of DkRb,
resulting in a 5:1 fluorophore to antibody molar ratio
in a total volume of 1 mL. The mixture was shaken
gently at room temperature for 3 h protected from
light. The resulting mixture was concentrated in 10
kDa molecular weight cut off spin filter (MWCO,
Amicon Ultra 0.5 mL 10 kDa, Fisher Scientific,
Waltham, MA) into a clean microcentrifuge tube to
remove unreacted fluorophore, followed by
purification through a 6 kDa MWCO desalting
column (Bio-Scale Mini Bio-Gel P-6 5 mL, Bio-Rad,
Hercules, CA) using a fast protein liquid
chromatography system (FPLC, NGC Quest 10 Plus,
Bio-Rad, Hercules, CA). The fluorophore to protein
ratio for each antibody conjugate was quantified
using absorbance spectroscopy (SpectraMax M5
Microplate Reader, Molecular Devices, Sunnyvale,
CA). The antibody absorbance was measured at 280
nm (Herceptin extinction coefficient = 225,000
http://www.thno.org
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M-1cm-1, Donkey anti-rabbit extinction coefficient =
210,000 M-1cm-1). Cy3B absorbance was measured at
560 nm (Cy3B extinction coefficient = 130,000
M-1cm-1), while AF647 absorbance was measured at
650 nm (AF647 extinction coefficient = 270,000
M-1cm-1). Calibrated absorbance and fluorescence
spectra and the Beer-Lambert law were used to
determine the concentration of fluorophore and
antibody
for
each
conjugate
[45].
All
fluorophore-to-antibody ratios used in this study
were between 3:1 and 4:1.
DDSI staining solution was made by mixing
Herceptin-AF647 with DkRb-Cy3B or Herceptin-Cy3B
with DkRb-AF647 in a solution containing 1x PBS pH
7.4, 0.1% Tween-20, and 1% bovine serum albumin
(BSA). Final antibody solution concentrations and
probe mixtures used for DDSI staining studies were
as follows: Herceptin-Cy3B + DkRb-AF647 at
concentrations of 100 and 200 nM measured by
protein concentration and Herceptin-AF647 +
DkRb-Cy3B at concentrations of 100 and 200 nM
measured by protein concentration.

Tumor Resection & DDSI Staining
MCF7-HER2 tumor bearing mice were
euthanized using CO2 asphyxiation followed by
cervical dislocation after 4-6 weeks of tumor growth
or a maximum tumor size of 1 cm3. Tumors were
extracted and bisected prior to DDSI staining, with
bisected pairs being used to test different staining
conditions. Bisection would not be necessary in
clinical use, but was performed in this study in order
to test multiple conditions using the same tumor for
increased control over potential variation in specimen
composition. For each bisected tumor sample, a
corresponding mammary adipose sample was
extracted from each mouse. MCF7-HER2 tumor and
mammary adipose samples were stained and washed
together following a previously published procedure
(Fig. 1A) [41]. Briefly, tumor and adipose sample pairs
were incubated in 1 mL of 2% BSA in PBS blocking
solution for 10 min. Then each sample pair was
incubated in 1 mL of DDSI staining solution for 1 or 10
min. Specimens were stained with both probes
simultaneously to minimize the required staining
time, making the technique feasible for integration
into routine clinical workflow. Each DDSI stained
sample pair was transferred to 50 mL of wash solution
composed of 0.1% Tween-20 in PBS and gently
agitated for 5 min. Tumor and adipose pairs were
immediately transferred to glass slides for imaging
with the bisected cut face facing up towards the light
source and camera. With two staining solutions at two
concentrations (100 and 200 nM) and two incubation
times (1 and 10 min) a total of 48 bisected tumor and
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mammary adipose pairs were collected resulting in
n=6 tissue pairs per DDSI staining condition for the
optimization
studies
(Fig.
1B).
Following
optimization, an additional testing cohort consisting
of n=6 MCF7-HER2 and n=6 MCF7 tumor specimens
were stained and imaged for validation of DDSI
method’s diagnostic ability and subsequent
immunohistochemical (IHC) analysis, making a total
of 60 tissue pairs stained and measured for this study.

DDSI Macroscopic Imaging
Tumor and adipose tissue pair imaging was
performed using a custom-built wide field imaging
system consisting of a QImaging EXi Blue
monochrome camera (Surrey, British Columbia, CA)
for fluorescence detection with a removable Bayer
filter for collecting co-registered color images [46-48].
A PhotoFluor II light source (89 North, Burlington,
VT) was focused onto the field of view (FOV, 34 mm ×
45 mm) through a liquid light guide and used
unfiltered for white light illumination. For
fluorescence excitation of the dual probe stain, the
PhotoFluor II was filtered with a 545 nm ± 12.5 nm or
620 nm ± 30 nm bandpass excitation filter for Cy3B or
AF647, respectively. The fluence rate for each channel
was 12 mW/cm2 and 15 mW/cm2 for the Cy3B and
AF647 excitation, respectively. Fluorescence was
collected with a 605 nm ± 35 nm or a 700 nm ± 37.5 nm
bandpass emission filter for Cy3B or AF647,
respectively. All filters were obtained from Chroma
Technology (Bellows Falls, VT). In addition to tumor
and adipose tissue pairs, an aliquot of each dual probe
staining solution in a covered optical well plate
(Greiner Bio-One, Monroe, NC) was imaged for
normalization
between
channels
and
stain
concentrations. Camera exposure times ranged from
10-50 ms and 150-500 ms for fluorescence image
collection of calibration drop images and tissue
specimens, respectively. Image resolution for
fluorescence and color images was 70 µm.

DDSI Image Processing
Co-registered images captured of targeted and
untargeted fluorescence were processed and used to
create DDSI images of each tumor-adipose tissue pair.
Image
processing
was
completed
using
custom-written MatLab Code (MathWorks, Natick,
MA). Image processing began by subtracting the
median background signal from the entire image in a
user selected region of interest (ROI) in which no
tissue was present. To account for any fluorescence
variance between experiments, the staining solutions
for each study were imaged and a user defined ROI
was quantified for each probe pair and concentration
used for staining. Images from each fluorescence
http://www.thno.org
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channel were normalized by dividing each pixel by
the average intensity value of the ROI representing
the DDSI staining solution corresponding to the probe
pair and concentration used for staining. A mask was
then applied to each normalized image so that only
pixels of measurable fluorescence (0.8-1.2x the
average pixel value of the area containing tissue) were
used in the DDSI image calculation. The DDSI image
was then calculated as IDDSI = (ITargeted – IUntargeted) /
IUntargeted. Tumor and normal tissue areas were
determined via user selected ROIs encompassing the
entire tissue area and intersected with the tissue mask
for statistical analysis.

Science University's (OHSU) Histology Shared
Resources. H&E and IHC slides were imaged using
the Zeiss AxioScan.Z1 Microscope (Zeiss). Bright field
images were obtained at 10x magnification. Using the
ZEN Slide scanner software, the ROI (tumor and
mammary adipose) was detected using Automatic
Tissue Recognition due to the visibility of the H&E
and IHC stains. Six field of views (FOVs) were used to
set the focus map. The ROI was then scanned at 10x
magnification, acquiring tiles over the entire tissue
specimen, which were automatically stitched by the
ZEN software to create the final image.

Confocal Microscopy

Statistical analysis was performed using MatLab.
To determine the tumor-to-normal adipose tissue
diagnostic detection ability, ROC curves were
generated for the untargeted probe images, targeted
probe images, and calculated DDSI images. ROC
curves and corresponding AUC measurements were
calculated using the perfcurve function in MatLab on
a pixel-by-pixel basis with individual pixel values for
each tissue type used as the response variable input.
Additionally, the optimal tumor vs. normal adipose
tissue threshold values were determined using the
ROC point generated from the perfcurve function and
back calculated to actual pixel value thresholds.
Histogram plots of the untargeted probe image,
targeted probe image and DDSI image pixel values for
tumor and normal adipose pixels were generated and
the optimal threshold point determined via ROC
curve analysis was plotted. Statistical significance
between staining conditions was determined using
the method described by Hanley and McNeil [50]
with standard error measurements and correlation
coefficients for pixel intensity values in each channel
used for z-score value calculations. z-score values >2
were considered statistically significant [50].
Sensitivity and specificity measurements were
determined for the testing dataset using the optimal
threshold value determined from the optimized DDSI
staining condition in the training optimization
studies.

Following macroscopic imaging, representative
tumor and adipose tissue pairs were imaged
immediately using the Zeiss LSM880 (Carl Zeiss
Microscopy GmbH, Jena, Germany) to collect high
resolution images of the targeted and untargeted
probe fluorescence. Using a plan-apochromatic 20x
(NA = 0.8) objective, images were collected with the
following settings: laser: 561 nm, 10% transmission
(DPSS 561-10, Cy3B); 633 nm, 2% transmission
(HeNe633,
AF647);
beam
splitter:
MBS
458/514/561/633; filter: 566-628 nm (Cy3B), 638-755
nm (AF647); pixel time: 1.5 μs; average: line 1; master
gain: 750 (Cy3B), 700 (AF647); pinhole size: 90 μm;
and acquisition area 512 × 512 pixels, 16-bit. Zen
imaging software (Zeiss) was used to merge each
fluorescence channel image colorimetrically with the
red channel representing Cy3B fluorescence and the
green channel representing AF647 fluorescence.

IHC Staining & Microscopy
Following imaging, each tumor and adipose
tissue pair was flash frozen in optimal cutting
temperature (OCT) compound for tissue preservation.
To enable IHC staining of each tissue pair, the OCT
blocks were thawed and re-embedded in paraffin for
sectioning, H&E staining, and HER2 IHC staining.
The tissue face imaged for DDSI analysis was placed
in the paraffin blocks so that it would be sectioned for
staining. All blocks were faced prior to collecting
serial sections for H&E and IHC staining, thus the
exact tissue face that was imaged for DDSI analysis
was not used for IHC staining. However, tissue
within a few hundred microns was used for IHC
analysis of HER2 expression levels. A different HER2
antibody (1:400, EP1045Y, ab134182, AbCam,
Cambridge, MA) targeted to the intracellular domain
of HER2 was used for IHC, to ensure staining of all
HER2 proteins, even those already stained with
Herceptin [49]. After paraffin embedding, H&E, and
IHC staining was performed by Oregon Health and

Statistical Analysis

Results
DDSI Staining Condition Optimization and
Qualitative Assessment of HER2 Expression by
IHC
Varied DDSI probe pairs (Herceptin-Cy3B +
DkRb-AF647, Herceptin-AF647 + DkRb-Cy3B), stain
solution concentrations (100 and 200 nM), and
staining incubation times (1 and 10 min) were
examined to establish a DDSI staining protocol with
speed and accuracy permitting both diagnostic
http://www.thno.org
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performance and clinical feasibility (Fig. 1B).
Qualitatively, DDSI images showed improved
tumor-to-adipose tissue contrast when compared to
untargeted or targeted probe images across all
conditions and probe pairs tested (Fig. 2). Upon
comparison, both probe pairs demonstrated the
ability to differentiate between tumor and adipose
tissues, showing that neither fluorophore label was
dominating the tissue biodistribution kinetics of the
targeted and untargeted probes [43, 51]. DDSI images
also showed more homogeneous intensities across
staining conditions and replicates compared to
targeted or untargeted single probe images (Fig. 2 &
S1). IHC assessment of HER2 staining patterns
revealed similar HER2 expression with DDSI staining
patterns across probe pairs and staining conditions
(Fig. 3). By comparison, HER2 IHC staining patterns
were not well aligned with single probe targeted
staining patterns, often showing inverse staining
patterns. Targeted and untargeted probes routinely
showed similar staining pattern to one another,
suggesting non-specific uptake dominated the
staining pattern. DDSI corrected for the non-specific
uptake, yielding staining patterns that were well
matched with the ground truth HER2 IHC staining
patterns (Fig. 3 & S2).

4728
Diagnostic Potential Quantification and
Optimal Staining Parameter Selection using
Training Tumor Xenograft Cohort
Untargeted, targeted, and DDSI image data was
quantified using ROC curve analysis to determine the
optimal probe pair and staining conditions. AUC for
each ROC curve was calculated to assess the ability to
differentiate tumor from adipose tissue for each tested
staining condition (Fig. 4A, 4B, & S3). DDSI
significantly improved tumor vs. normal adipose
tissue AUC values when compared to targeted single
probe staining alone across all DDSI probe pairs and
tested staining conditions (Fig. 4, Table 1). These
results are in agreement with a similar and promising
analysis performed in human breast cancer specimens
using dual probe ratiometric imaging of SERS
nanoparticles to guide tumor margin assessment [52].
The highest three AUC values were generated using
the 200 nM, 10 min staining condition for the
Herceptin-AF647 + DkRb-Cy3B probe pair (AUC =
0.989), 100 nM, 10 min staining condition for the
Herceptin-Cy3B + DkRb-AF647 probe pair (AUC =
0.978), and 200 nM, 1 min staining condition for the
Herceptin-AF647 + DkRb-Cy3B probe pair (AUC =
0.974) (Fig. 4A, 4B, & S3).

Fig. 2: DDSI staining condition optimization. Representative color, fluorescence, and DDSI images of tumor and adipose tissue pairs following staining using a
range of dual-stain soak concentrations and incubation times for (A) probe pair A (Herceptin-Cy3b, DkRb-AF647) and (B) probe pair B (Herceptin-AF647,
DkRb-Cy3b). All images are representative of data collected for n=6 tumor and adipose tissue pairs per staining condition. All untargeted and targeted channel images
are background corrected, normalized by their exposure time and calibration drop intensity, and displayed on equivalent color scales across staining conditions and
probe pairs. DDSI images are displayed with equivalent color scales across staining conditions. Scale bars = 5 mm.
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Fig. 3: Immunohistochemical analysis and DDSI staining pattern validation. Representative color, fluorescence, DDSI, H&E, and HER2 targeted IHC
images of tumor and adipose tissue pairs following staining using a range of dual-stain soak concentrations and incubation times for (A) probe pair A (Herceptin-Cy3b,
DkRb-AF647) and (B) probe pair B (Herceptin-AF647, DkRb-Cy3b). All images are representative of data collected for n=6 tumor and adipose tissue pairs per
staining condition. All untargeted and targeted channel images are background corrected, normalized by their exposure time and calibration drop intensity. DDSI
images are displayed with equivalent color scales across staining conditions. H&E and IHC images were acquired from serial sections of the same tissue face imaged
in the whole specimen DDSI images. H&E: hematoxylin and eosin; IHC: immunohistochemistry. Scale bars = 5 mm.

Table 1: ROC AUC values and z-statistics for DDSI stain condition optimization.
Probe Pair A
Targeted: Herceptin-Cy3B, Untargeted: Dk-anti-Rb-AF647
Incubation Time:

Stain
Concentration:
100 nM

1 min
T

DDSI

UT

T

DDSI

0.532

0.866

0.965

0.586

0.930

0.978

155.7

z-stat:

UT

T

DDSI

UT

T

DDSI

0.880

0.973

0.491

0.844

0.906

172.2

z-stat:

100 nM

114.6

0.488
z-stat:

Incubation Time:

Stain
Concentration:

10 min

UT
z-stat:
200 nM

Probe Pair B
Targeted: Herceptin-AF647, Untargeted: Dk-anti-Rb-Cy3B

163.0

1 min
T

DDSI

UT

T

0.705

0.928

0.929

0.612

0.921

z-stat:
200 nM

10 min

UT

3.1

z-stat:

UT

T

DDSI

UT

T

0.962

0.974

0.736

0.977

29.8

0.958
72.1

0.715
z-stat:

DDSI

z-stat:

DDSI
0.989
48.2

*UT: untargeted channel; T: targeted channel; ROC: receiver operator characteristic; AUC: area under curve; z-stat: z-statistic obtained from comparison of targeted vs. DDSI
ROC AUC values for each staining condition (z-stat > 2 signifies significantly different AUC values).

The 200 nM, 1 min staining condition using the
Herceptin-AF647 + DkRb-Cy3B probe pair was
chosen as the optimal staining condition since its AUC
was not appreciably different than the 10 min staining
conditions and the 1 min incubation time would be
more clinically feasible for margin assessment in the
operating room. Histograms of the untargeted,
targeted, and DDSI pixel values demonstrated the
improved separation of intensity distribution between
MCF7-HER2 tumor and normal adipose tissue using
the DDSI method compared to the targeted or
untargeted probe alone (Fig. 4C). Additionally, a
more normal distribution for both tissue types was
obtained using DDSI compared to the single probe

targeted stain, signifying the improvement in ROC
AUC values (Fig. 4C) and intensity normalization
between replicates as a result of DDSI (Fig. S1).
Additionally, the optimal cutoff values determined
using ROC curve analysis were plotted on the
untargeted, targeted, and DDSI histograms to
demonstrate the ability to perform automated
differentiation between tumor and adipose tissue
using a single threshold.

Optimal DDSI Method Validation in
MCF7-HER2 and MCF7 Testing Tumor
Xenograft Cohort
The selected probe pair (Herceptin-AF647 +
http://www.thno.org

Theranostics 2017, Vol. 7, Issue 19
Dk-Rb-Cy3B) and staining condition (200 nM, 1 min)
was applied to a testing MCF7-HER2 (HER2+) paired
tumor and normal adipose tissue cohort and to a
matched MCF7 (HER2-) tumor and normal adipose
tissue cohort for validation of the diagnostic potential
of the optimized DDSI staining condition (Fig. 5 & S4).
MCF7-HER2 tumors stained using the optimal probe
pair and staining conditions demonstrated similar
improvements in DDSI tumor vs. normal adipose
AUC values when compared to the single probe
targeted stain (Targeted AUC = 0.84, DDSI AUC =
0.95, z = 131.0). Additionally, similar optimal cutoff
values to the staining condition optimization training
MCF7-HER2 tumor cohort were determined for the
testing cohort upon ROC curve analysis (Fig 5C).
Applying the optimal threshold value determined
from the training cohort (Fig. 4C) to the testing cohort
(Fig. 5C) provided a sensitivity of 91% and a
specificity of 84% for tumor vs. normal tissue
differentiation. The MCF7 tumor cohort stained using
the selected probe pair and staining conditions
demonstrated significantly lower DDSI image
intensities and DDSI tumor vs. normal adipose tissue
AUC values compared to the MCF7-HER2 tumor
cohort. Additionally, the tumor vs. normal adipose
tissue AUC value was decreased from 0.67 for the
single probe targeted stain to 0.50 for DDSI in the
MCF7 tumor line tumor. This was the expected
behavior as MCF7 is a HER2 negative cell line that
should not generate HER2 specific signal; however,
when targeted probe alone was assessed, some
nonspecific uptake of HER2 was seen (AUC = 0.67),
which was corrected using the DDSI protocol (AUC =
0.50). HER2 targeted IHC completed on the same
representative tissue confirmed the expected HER2
overexpression in MCF7-HER2 tumors, which was
again closely matched with the DDSI pattern.
Furthermore, high resolution images of the targeted
probe and IHC staining pattern confirmed the
membrane bound fluorescence staining pattern
expected from HER2 targeted imaging (Fig. S5). HER2
IHC staining showed minimal HER2 expression in
MCF7 parent line tumors, supporting the DDSI AUC
of 0.50 between tumor and normal tissues based on
HER2 expression (Fig. 5).

Discussion
The primary aims of this study were to optimize
and validate the DDSI staining technique for
improved tumor margin assessment during BCS.
Incomplete tumor resection during BCS plagues
surgical outcomes, requiring expensive, invasive
follow-up surgery, increasing the chances of
morbidity, and negatively affecting patient outcomes
[2-6]. Contrast guided resection techniques have
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shown promise for improved margin assessment
using molecularly specific probes [53, 54]; however
clinical translation of contrast agents for in vivo
applications remains challenging. To circumvent
these difficulties, staining of the resected tumor
specimens has gained in popularity. However
non-specific contrast uptake dominates resected
specimen staining, significantly decreasing tumor to
normal tissue contrast. Using our novel DDSI
technique, non-specific uptake can be overcome and
excised tumor tissue can be distinguished from
normal tissue with high sensitivity and specificity
[41].
In the present study, we examined a wide range
of staining conditions where probe concentration,
staining time and fluorophore were varied from
conditions used in the prior proof-of-concept study to
identify a suitable protocol for future clinical studies
(Fig. 1). We evaluated the diagnostic performance of a
single condition, which could both minimize staining
time and optimize diagnostic potential. The
diagnostic potential was evaluated using a
semi-blinded, pre-clinical study through ROC curve
analysis on a training data set to define an optimal
diagnostic threshold and applied prospectively to a
testing data set that included normal tissue, HER2(+)
tumors and HER2(-) tumors.
The DDSI staining conditions tested provided a
robust and rapid diagnostic technique for
intraoperative tumor margin assessment. Across both
fluorescent probe pairs and all staining conditions,
DDSI showed improved tumor to normal adipose
tissue differentiation as compared to targeted probe
alone (Fig. 2, Fig. 4A & 4B). The fluorophore labels
chosen for this study, AF647 and Cy3B, did not
significantly affect DDSI performance, with consistent
tumor to normal adipose tissue differentiation across
both fluorophore antibody probe pairs. While probe
pair B demonstrated an increase in DDSI values
compared to probe pair A, this increase occurred in
both tumor and normal tissue equally, causing
negligible overall change in probe pair B’s diagnostic
ability over probe pair A (Fig. 2, Fig. 4A & 4B).
Additionally, the DDSI protocol normalized tumor
HER2 intensities between staining conditions, where
intensities were significantly less affected by the
varied staining parameters than single targeted probe
intensities (Fig. S1). The selected optimal staining
condition provided high tumor vs. normal tissue
sensitivity (97%) and specificity (89%) determined via
retrospective ROC curve analysis with a 1 min
incubation in a 200 nM solution of the
Herceptin-AF647 + DkRb-Cy3B probe pair (Fig. 4C)
decreasing overall staining time and imaging time to a
total of 16 min, while improving ability to
http://www.thno.org
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differentiate between benign and malignant tissues.
Importantly, DDSI staining does not interfere
with downstream pathology, enabling utilization of
current gold standard diagnostic methods to validate
intraoperative observations for first in human clinical
trials. As a demonstration, DDSI staining patterns
were correlated to HER2 expression using HER2
targeted IHC (Fig. 3). DDSI staining patterns were
found to closely align with HER2 expression levels
and patterns across staining conditions. By
comparison, single probe targeted staining patterns
were not well aligned with IHC staining patterns,
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with higher targeted fluorescence intensities in
regions of low HER2 IHC expression (Fig. 3). These
results demonstrate that the DDSI method
accommodates non-specific uptake of the targeted
probe as well as other imaging anomalies inherent to
single probe optical imaging such as variations in
imaging system illumination power, detector
non-uniformities, detector working distance, etc.
Thus, DDSI provided the ability to rapidly visualize
biomarker-bound fluorescence, enabling specific
molecularly-targeted imaging to be completed on
resected tissues.

Fig. 4: ROC curve analysis and optimal DDSI staining condition selection. ROC curves and AUC values for untargeted, targeted, and DDSI images of
tumor vs. normal adipose tissue differentiation following staining using a range of dual-stain soak concentrations and incubation times for (A) probe pair A
(Herceptin-Cy3b, DkRb-AF647) and (B) probe pair B (Herceptin-AF647, DkRb-Cy3b). (C) Tumor and normal tissue pixel intensity histograms, ROC curves, and
AUC values for untargeted, targeted, and DDSI images following staining using probe pair B at 200 nM concentration and 1 min incubation time. Optimal points
determined from ROC curve analysis are displayed on each ROC curve and as a vertical line on each pixel value histogram. ROC: receiver operator characteristic;
AUC: area under curve; opt pt: optimal point.
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Fig 5: HER2(+) and HER2(-) testing cohort for DDSI staining and IHC validation. (A) Representative color, fluorescence, DDSI, H&E, and HER2 targeted
IHC images of MCF7-HER2 (HER2+) and MCF7 (HER2-) tumor and adipose tissue pairs following staining using the optimal staining condition (Probe pair B, 200 nM
concentration, 1 min incubation time). All images are representative of data collected for n=6 tumor and adipose tissue pairs per tumor cell line. All untargeted and
targeted channel images are background corrected, normalized by their exposure time and calibration drop intensity, and displayed on equivalent color scales. DDSI
images are displayed with equivalent color scales. H&E and IHC images were acquired from serial sections of the same tissue face imaged in the whole DDSI specimen
images. Scale bars = 5 mm. (B) Tumor and normal tissue pixel intensity histograms, (C) ROC curves, and AUC values for untargeted, targeted, and DDSI images
corresponding to each cell line. Optimal points determined from ROC analysis are displayed on each ROC curve (blue marker) and as a vertical line on each pixel
value histogram. The optimal point determined from the training cohort data is displayed on the MCF7-HER2 tumor specimen ROC curve to demonstrate the
diagnostic reproducibility under optimal staining conditions (orange marker). H&E: Hematoxylin & Eosin; IHC: immunohistochemistry; ROC: receiver operator
characteristic; AUC: area under curve; opt pt: optimal point.

The performance of the selected DDSI protocol
was confirmed in an independent testing tumor
cohort consisting of HER2+ (MCF7-HER2) and HER2(MCF7) tumor specimens. The HER2+ testing dataset
showed similar diagnostic AUC and optimal cutoff
values to the prior HER2+ training dataset,
demonstrating the repeatability and robustness of the
DDSI staining and analysis method. Applying the
optimal threshold calculated from training dataset
values, high tumor vs. normal tissue sensitivity (91%)
and specificity (84%) was achieved. As expected, the
HER2- testing dataset showed lower DDSI signal
intensities and AUC values compared to the HER2+
tumor line (Fig. 5). Notably, for HER2- tumor
specimens, both targeted and untargeted AUC values
were above 0.50, signifying higher uptake in the
tumor tissue compared to the normal adipose tissue
even though the tissue lacked the HER2 biomarker.
DDSI was able to correct for this nonspecific uptake of
the targeted stain by the HER2- tumor tissue, bringing
the AUC value back down to the expected value of
0.50. These results validate the ability to provide
specific molecular imaging on resected tissues with
the DDSI technique.
Continued stain protocol development will be
necessary to further reduce the overall staining time
generating a clinically relevant staining protocol.
Total resected specimen staining time could be
additionally reduced by optimizing the washing and
blocking conditions, which can likely be reduced to

<10 min for rapid margin assessment in the operating
room. Expanding and screening this technique with a
panel of tumor specific biomarkers such as epidermal
growth factor receptor (EGFR), estrogen receptor
(ER), and progesterone receptor (PgR) for breast
cancer, is also needed to utilize DDSI tumor margin
assessment on patient specimens with varied tumor
subtype, heterogeneous cellular phenotypes and
expression patterns, where multiplexed biomarker
imaging could be achieved through the addition of
other targeted fluorescence channels [55, 56]. This will
facilitate translation of the DDSI technique to human
specimens excised during BCS for complete
validation of this promising technique for margin
detection during BCS. Although studies testing mixed
tumor and adipose samples are not feasible using
xenograft models, DDSI staining on resected human
breast tissue samples composed of varying
percentages of tumor and adipose mixed tissues will
be imperative for validation of the clinical diagnostic
performance of the DDSI method.
The animal model system used for this study
provided a controlled platform that allowed
examination of several different processing conditions
and probe pairs; however, as with any translational
animal study, the model system has its limitations in
recapitulating the challenges in diagnosing human
tissue. The small normal tissue volumes and lack of
infiltrative tumor growth patterns are relevant
limitations of mouse models for this application.
http://www.thno.org
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However, the dual-probe technique is designed to
accommodate/remove the effects of diffusion and
other non-specific kinetic behavior regardless of tissue
type and structure, and our results suggest that the
DDSI parameter is indeed reporting receptor-specific
information. These results also provide a robust,
evidenced-based protocol for translation to humans.
The next phase of development involves validating
the optimal stain protocol identified herein on thick
slices of discarded human breast specimens from
tumor mastectomy patients and then initiating an
observational clinical study in the operating room.
In summary, the selected DDSI staining
technique showed significant improvement in
distinguishing tumor from normal adipose tissue in
excised specimens over targeted staining alone.
Perturbations in antibody-fluorophore probe pairs
had little effect on DDSI performance with consistent
tumor vs. normal tissue diagnostic performance
across all tested staining conditions. Using antibody
based probes and visible fluorophores, the probe
penetration and imaging depth are inherently surface
weighted and likely limited to a few microns at best.
However, according to new consensus criteria for
breast cancer margin status, margins are considered to
be negative for tumor when there is no tumor at the
“ink” or surface of the resected specimen, making the
current probe composition viable for clinical
translation [57]. DDSI was also demonstrated to be an
accurate reporter of tumor specific molecular
expression levels of HER2, and provided a validated
diagnostic method for intraoperative tumor margin
detection with high sensitivity and specificity for BCS.
The DDSI framework is generalizable to surgical
resection of other cancers, and we are actively
studying its application for other indications. With
further development and application to a range of
cancer biomarkers, this technique could provide the
ability to identify diverse cancer phenotypes for
improved tumor margin assessment intraoperatively,
reducing re-excision rates and improving patient
outcomes.
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